Cellectis S.A.

CLLS Nasdaq CIK: 0001627281

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
SEC Category Accelerated filer
State of Incorporation France
Country France
Business Address 8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE, ,
Mailing Address 8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE, ,
Phone 33181691600
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
6-K Foreign company current report March 20, 2026 View on SEC
20-F Foreign company annual report March 20, 2026 View on SEC
6-K Foreign company current report March 12, 2026 View on SEC
6-K Foreign company current report January 8, 2026 View on SEC
6-K Foreign company current report December 15, 2025 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment December 12, 2025 View on SEC
6-K Foreign company current report December 8, 2025 View on SEC
6-K Foreign company current report December 5, 2025 View on SEC
6-K Foreign company current report November 19, 2025 View on SEC
6-K Foreign company current report November 7, 2025 View on SEC

Annual Reports

20-F March 20, 2026
  • Formed a significant partnership with AstraZeneca in November 2023, validating its gene-editing technology and securing funding.
  • Strategically refocused on its core 'off-the-shelf' CAR T-cell programs for cancer by selling Calyxt Inc. in May 2023.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.